Arbutus Biopharma (ABUS) Non-Current Debt (2016 - 2017)
Arbutus Biopharma (ABUS) posted quarterly Non-Current Debt of $12.0 million for Q4 2017, little changed year-on-year from $12.0 million in Q4 2016, and little changed on a QoQ basis from $12.0 million in Q3 2017.
Arbutus Biopharma (ABUS) Non-Current Debt (2016 - 2017) Analysis & Trends
Arbutus Biopharma (ABUS) has reported Non-Current Debt for 2 consecutive years, with $12.0 million the latest figure, recorded in Q4 2017.
- Quarterly Non-Current Debt changed 0.0% year-over-year to $12.0 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $12.0 million (changed 0.0% YoY) and the FY2017 annual result came in at $12.0 million, changed 0.0% from the prior year.
- Non-Current Debt was little changed at $12.0 million in Q4 2017 per ABUS's latest filing, from $12.0 million in the prior quarter.
- Over the last five years, Non-Current Debt for ABUS reached as high as $12.0 million in Q4 2016 and fell as low as $12.0 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 12.00 Mn |
| Sep 30, 2017 | 12.00 Mn |
| Jun 30, 2017 | 12.00 Mn |
| Mar 31, 2017 | 12.00 Mn |
| Dec 31, 2016 | 12.00 Mn |